This review summarizes the cardiovascular effects of ivabradine, highlighting its efficacy in heart rate reduction and safety profile in patients with stable angina and post-myocardial infarction.
Answers are grounded in this paper and cite their sources.
May support ivabradine for stable angina; leaves open need for new RCTs on post-MI remodelling.
Ivabradine (a compound of the benzocyclobutane) is a highly selective I(f) current inhibitor acting directly on the sino-atrial node, induces a rapid, sustained and dose-dependent reduction of heart rate at rest and during exercise without a significant effect on atrio-ventricular conduction, left ventricular contraction/relaxation or vascular tissues. These properties associated with an improvement in left ventricular loading related to bradycardia resulted in an increase in stroke volume and preservation in cardiac output even during exercise. Various experimental and clinical studies showed the efficacy of ivabradine in patients with chronic stable angina, on heart rate reduction, on ventricular remodelling after acute myocardial infarction and on coronary blood flow. The safety of ivabradine has been documented in several studies and clinical trials, in contrast to beta-blockers, no significant side effects were expressed in the literature. The aim of our review is to describe ivabradine and its cardiovascular effects and outline some recent patents and the results of the most important trials.
No takes yet. Share an insight, caveat, or question.
Rognoni et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: